Evidence map›Paper›PMID 40666533›Full record

ReviewMediastinum (Hong Kong, China)2025

Hyperthermic intrathoracic chemotherapy (HITHOC) in stage IVA thymomas: a narrative review.

Paolo Mendogni, Riccardo Orlandi, Marcello Ambrogi, Marco Lucchi, Filippo Lococo, Enrico Ruffini, Stefano Margaritora, Dirk Van Raemdonck, Tom Vandaele, Laurens J Ceulemans and 1 more

Abstract readReview
In one paragraph

Review in Mediastinum (Hong Kong, China), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Hyperthermic intrathoracic chemotherapy in the management of pleural malignancies: current evidence, limitations, and future directions.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Present and future of cytoreductive surgery and hyperthermic intrathoracic chemotherapy for pleural metastases: a narrative review.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Paolo MendogniThoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Riccardo OrlandiDepartment of Thoracic Surgery, University of Milan, Milan, Italy.ORCID https://orcid.org/0000-0002-4113-1598
Marcello AmbrogiDivision of Thoracic Surgery, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
Marco LucchiDivision of Thoracic Surgery, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
Filippo LococoThoracic Surgery Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.
Enrico RuffiniDepartment of Thoracic Surgery, University of Torino, Torino, Italy.
Stefano MargaritoraThoracic Surgery Unit, A. Gemelli University Hospital Foundation IRCCS, Rome, Italy.
Dirk Van RaemdonckDepartment of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium.
Tom VandaeleDepartment of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium.
Laurens J CeulemansDepartment of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium.
Lorenzo RossoThoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objective: While surgery remains a cornerstone of thymoma treatment, its role as a standalone therapy is limited in ensuring adequate local disease control, particularly in cases involving serous dissemination or recurrence. For disseminated disease, various multidisciplinary approaches have been explored, including systemic chemotherapy and radiotherapy, either as standalone treatments or in combination with surgery. The efficacy is unsatisfactory, and the management is anything but standardized. However, recently, a promising technique has been introduced within the therapeutic algorithm of advanced stage thymomas: the hyperthermic intrathoracic chemotherapy (HITHOC) as an adjunct to surgery. By combining cytoreductive surgery with localized heated chemotherapy perfusion, HITHOC may help in treating residual disease, providing a targeted approach to pleural dissemination. HITHOC has demonstrated efficacy in managing stage IVA thymomas and thymoma-related pleural recurrences, establishing itself as a potential critical component of modern multimodal treatment strategies. This narrative review aims at providing a detailed examination of the mechanisms, indications, procedural aspects, and outcomes of HITHOC in pleural localization of thymomas, as well as its future potential in thoracic oncology. Methods: A literature search was performed using the MEDLINE and Google Scholar databases, including original full-length articles, meta-analyses, review articles, and case reports published up to January 2025. Key Content and Findings: HITHOC has been developed as an adjunct to macroscopic radical pleural tumor resection. By enhancing local tumor control and lowering recurrence rates, HITHOC provides a valuable addition to the multimodal treatment of advanced thymomas. Conclusions: HITHOC may represent a promising approach in the treatment of advanced thymomas with pleural dissemination. By combining cytoreductive surgery with localized hyperthermic chemotherapy, it may address the limitations of conventional therapies, potentially offering improved local disease control and survival.

Indexed as

cytoreductivehyperthermic intrathoracic chemotherapy (HITHOC)multidisciplinaryThymoma

Identifiers

PMID40666533
PMCPMC12260944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.